CLAIMS

What is claimed is:

- 1. A composition comprising an isolated polynucleotide encoding a protein having TNF-R1-DD ligand protein activity.
- 5 2. The composition of claim 1 wherein said polynucleotide is selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 2 to nucleotide 1231;
 - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1;
 - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:2;
 - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:2; and
 - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).
 - 3. The composition of claim 1 wherein said polynucleotide sequence is selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 2 to nucleotide 415;
 - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3;
 - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:4;
 - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:4; and
 - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).

30

10

15

20

5	4.	A con	nposition of claim 1 wherein said polynucleotide is operably linked
	to an express	ion con	trol sequence.
	5.	A hos	st cell transformed with a composition of claim 4.
10	6.	The h	ost cell of claim 5, wherein said cell is a mammalian cell.
	7.	A pr	ocess for producing an TNF-R1-DD ligand protein, which
	comprises:		
		(a)	growing a culture of the host cell of claim 5 in a suitable culture
15	mediu	ım; and	
		(b)	purifying the TNF-R1-DD ligand protein from the culture.
	8.	A cor	nposition comprising a protein having TNF-R1-DD ligand protein
	activity.		
20			
	9.	The c	composition of claim 8 wherein said protein comprises an amino
	acid sequence	e select	ed from the group consisting of:
		(a)	the amino acid sequence of SEQ ID NO:2; and
		(b)	fragments of the amino acid sequence of SEQ ID NO:2;
25	said protein b	peing su	bstantially free from other mammalian proteins.
	10.	The c	composition of claim 8 wherein said protein comprises an amino
	acid sequence	e select	ed from the group consisting of:
		(a)	the amino acid sequence of SEQ ID NO:4; and
30		(b)	fragments of the amino acid sequence of SEQ ID NO:4;
	said protein b	peing su	bstantially free from other mammalian proteins.
	11.	The c	composition of claim 8 wherein said protein comprises an amino
	acid sequence	e select	ed from the group consisting of:
35		(a)	the amino acid sequence of SEQ ID NO:6; and
		(b)	fragments of the amino acid sequence of SEO ID NO:6:

20

5	said protein being substantially free from other mammalian proteins.								
	12.	The composition of claim 8, further comprising a pharmaceutically							
	acceptable ca	urrier.							

- 10 13. A composition comprising an antibody which specifically reacts with the TNF-R1-DD ligand protein of claim 8.
 - 14. A method of identifying an inhibitor of TNF-R death domain binding which comprises:
 - (a) combining an TNF-R death domain protein with a composition of claim 8, said combination forming a first binding mixture;
 - (b) measuring the amount of binding between the TNF-R death domain protein and the TNF-R1-DD ligand protein in the first binding mixture;
 - (c) combining a compound with the TNF-R death domain protein and an TNF-R1-DD ligand protein to form a second binding mixture;
 - (d) measuring the amount of binding in the second binding mixture; and
 - (e) comparing the amount of binding in the first binding mixture with the amount of binding in the second binding mixture;
- wherein the compound is capable of inhibiting TNF-R death domain binding when a decrease in the amount of binding of the second binding mixture occurs.
 - 15. The method of claim 14 wherein said TNF-R1-DD ligand protein comprises an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:2;
 - (b) fragments of the amino acid sequence of SEQ ID NO:2;
 - (c) the amino acid sequence of SEQ ID NO:4;

5		(d)	fragments of the amino acid sequence of SEQ ID NO:4;
		(e)	the amino acid sequence of SEQ ID NO:6;
		(f)	fragments of the amino acid sequence of SEQ ID NO:6;
		(g)	the amino acid sequence of SEQ ID NO:8; and
		(h)	fragments of the amino acid sequence of SEQ ID NO:8.
10			
	16.	A me	thod of preventing or ameliorating an inflammatory condition
	which compri	ses adn	ninistering a therapeutically effective amount of a composition of
	claim 12.		
15	17.	TNF-	R1-DD ligand protein produced according to the method of claim
	7.		
	18.		ethod of inhibiting TNF-R death domain binding comprising
	administering	a thera	speutically effective amount of a composition of claim 12.
20			
	19.		thod of preventing or ameliorating an inflammatory condition
	•		ministering to a mammalian subject a therapeutically effective
		•	ion comprising a pharmaceutically acceptable carrier and a protein
		_	up consisting of IGFBP-5 and fragments thereof having TNF-R1-
25	DD ligand pr	otein ac	tivity.
	20	A	at a finkihiting TNT D doeth domain kinding commission
	20.		ethod of inhibiting TNF-R death domain binding comprising
	•		mammalian subject a therapeutically effective amount of a
20	*	•	sing a pharmaceutically acceptable carrier and a protein selected
30	from the grou	p consis	sting of IGFBP-5 and fragments thereof having TNF-R1-DD ligand

21. A composition comprising an inhibitor identified according to the method of claim 14.

35

protein activity.

20

- 5 22. The composition of claim 21 further comprising a pharmaceutically acceptable carrier.
- 23. A method of preventing or ameliorating an inflammatory condition comprising administering to a mammalian subject a therapeutically effective amount of the composition of claim 22.
 - 24. A method of inhibiting TNF-R death domain binding comprising administering to a mammalian subject a therapeutically effective amount of the composition of claim 22.
 - 25. A composition comprising a pharmaceutically acceptable carrier and a protein selected from the group consisting of IGFBP-5 and fragments thereof having TNF-R1-DD ligand protein activity.
 - 26. A method of identifying an inhibitor of TNF-R death domain binding which comprises:
 - (a) transforming a cell with a first polynucleotide encoding an TNF-R death domain protein, a second polynucleotide encoding an TNF-R1-DD ligand protein, and at least one reporter gene, wherein the expression of the reporter gene is regulated by the binding of the TNF-R1-DD ligand protein encoded by the second polynucleotide to the TNF-R death domain protein encoded by the first polynucleotide;
 - (b) growing the cell in the presence of and in the absence of a compound; and
- 30 (c) comparing the degree of expression of the reporter gene in the presence of and in the absence of the compound;
 wherein the compound is capable of inhibiting TNF-R death domain binding when a decrease in the degree of expression of the reporter gene occurs.
- The method of claim 26 wherein the second polynucleotide is selected from the group consisting of:

5	(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
	NO:1 from nucleotide 2 to nucleotide 1231;
	(b) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:1, which encodes a protein having TNF-R1-DD ligand
	protein activity;
10	(c) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:2;
	(d) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:2 and having
	TNF-R1-DD ligand protein activity;
15	(e) a polynucleotide comprising the nucleotide sequence of SEQ ID
	NO:3 from nucleotide 2 to nucleotide 415;
	(f) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:3, which encodes a protein having TNF-R1-DD ligand
	protein activity;
20	(g) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:4;
	(h) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:4 and having
	TNF-R1-DD ligand protein activity;
25	(i) a polynucleotide comprising the nucleotide sequence of SEQ ID
	NO:5 from nucleotide 2 to nucleotide 559;
	(j) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:5, which encodes a protein having TNF-R1-DD ligand
	protein activity;
30	(k) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:6;
	(l) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:6 and having
	TNF-R1-DD ligand protein activity;
35	(m) a polynucleotide comprising the nucleotide sequence of SEQ ID
	NO:7 from nucleotide 57 to nucleotide 875;

5	(n) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:7, which encodes a protein having TNF-R1-DD ligano
	protein activity;
	(o) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:8;
10	(p) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:8 and having
	TNF-R1-DD ligand protein activity; and
	(q) a polynucleotide capable of hybridizing under stringent
	conditions to any one of the polynucleotides specified in (a)-(p), which encodes
15	a protein having TNF-R1-DD ligand protein activity.
	28. The method of claim 26 wherein the cell is a yeast cell.
	29. The composition of claim 1 wherein said polynucleotide sequence is
20	selected from the group consisting of:
	(a) a polynucleotide comprising the nucleotide sequence of SEQ II
	NO:9 from nucleotide 2 to nucleotide 931;
	(b) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:9;
25	(c) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:10;
	(d) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:10; and
	(e) a polynucleotide capable of hybridizing under stringen
30	conditions to any one of the polynucleotides specified in (a)-(d).
	7
	30. The composition of claim 1 wherein said polynucleotide sequence is
	selected from the group consisting of:
	(a) a polynucleotide comprising the nucleotide sequence of SEQ II
35	NO:11 from nucleotide 2 to nucleotide 1822;

5	(b) a polynucleotide comprising a fragment of the nucleotide					
	sequence of SEQ ID NO:11;					
	(c) a polynucleotide encoding an TNF-R1-DD ligand protein					
	comprising the amino acid sequence of SEQ ID NO:12;					
	(d) a polynucleotide encoding an TNF-R1-DD ligand protein					
10	comprising a fragment of the amino acid sequence of SEQ ID NO:12; and					
	(e) a polynucleotide capable of hybridizing under stringent					
	conditions to any one of the polynucleotides specified in (a)-(d).					
	31. The composition of claim 8 wherein said protein comprises an amino					
15	acid sequence selected from the group consisting of:					
	(a) the amino acid sequence of SEQ ID NO:10; and					
	(b) fragments of the amino acid sequence of SEQ ID NO:10;					
	said protein being substantially free from other mammalian proteins.					
20	32. The composition of claim 8 wherein said protein comprises an amino					
20	acid sequence selected from the group consisting of:					
	(a) the amino acid sequence of SEQ ID NO:12; and					
	(b) fragments of the amino acid sequence of SEQ ID NO:12;					
	said protein being substantially free from other mammalian proteins.					
25	said protein being substantially free from other manimalian proteins.					
23	33. The method of claim 14 wherein said TNF-R1-DD ligand protein					
	comprises an amino acid sequence selected from the group consisting of:					
	(a) the amino acid sequence of SEQ ID NO:10;					
	•					
20	(b) fragments of the amino acid sequence of SEQ ID NO:10;					
30	(c) the amino acid sequence of SEQ ID NO:12; and					
	(d) fragments of the amino acid sequence of SEQ ID NO: F2.					
	34. The method of claim 26 wherein the second polynucleotide is selected					
	from the group consisting of:					
35	(a) a polynucleotide comprising the nucleotide sequence of SEQ ID					
	NO:9 from nucleotide 2 to nucleotide 931;					

5	(b) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:9, which encodes a protein having TNF-R1-DD ligand
	protein activity;
	(c) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:10;
10	(d) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:10 and
	having TNF-R1-DD ligand protein activity;
	(e) a polynucleotide comprising the nucleotide sequence of SEQ ID
	NO:11 from nucleotide 2 to nucleotide 1822;
15	(f) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:11, which encodes a protein having TNF-R1-DD
	ligand protein activity;
	(g) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:12; and
20	(h) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:12 and
	having TNF-R1-DD ligand protein activity; and
	(i) a polynucleotide capable of hybridizing under stringent
	conditions to any one of the polynucleotides specified in (a)-(h), which encodes
25	a protein having TNF-R1-DD ligand protein activity.
	35. The composition of claim 1 wherein said polynucleotide sequençe is
	selected from the group consisting of:
	(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
30	NO:13 from nucleotide 3 to nucleotide 2846;
	(b) a polynucleotide comprising a fragment of the nucleotide
	sequence of SEQ ID NO:13;
	(c) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising the amino acid sequence of SEQ ID NO:14;
35	(d) a polynucleotide encoding an TNF-R1-DD ligand protein
	comprising a fragment of the amino acid sequence of SEQ ID NO:14; and

25

5		(e)	a	polynucleotide	capable	of	hybridizing	under	stringent
	condi	tions to	any	one of the polyr	ucleotide	s sp	ecified in (a)-	·(d).	
	36.	The co	omį	position of claim	8 wherei	n sa	id protein cor	nprises	an amino
	acid sequence	selecte	d fi	om the group co	nsisting o	f:		•	

- (a) the amino acid sequence of SEQ ID NO:14; and
- (b) fragments of the amino acid sequence of SEQ ID NO:14; said protein being substantially free from other mammalian proteins.
- 37. The method of claim 14 wherein said TNF-R1-DD ligand protein comprises an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:14; and
 - (b) fragments of the amino acid sequence of SEQ ID NO:14.
- 38. The method of claim 26 wherein the second polynucleotide is selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 3 to nucleotide 2846;
 - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:13, which encodes a protein having TNF-R1-DD ligand protein activity;
 - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:14;
 - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 and having TNF-R1-DD ligand protein activity; and
 - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having TNF-R1-DD ligand protein activity.
- 35 39. The composition of claim 1 wherein said polynucleotide sequence is selected from the group consisting of:

5		(a)	a polynucleotide comprising the nucleotide sequence of SEQ ID
-	NO:1	5 from	nucleotide 326 to nucleotide 5092;
		(b)	a polynucleotide comprising a fragment of the nucleotide
	seque	nce of	SEQ ID NO:15;
		(c)	a polynucleotide encoding an TNF-R1-DD ligand protein
10	comp	rising t	he amino acid sequence of SEQ ID NO:16;
		(d)	a polynucleotide encoding an TNF-R1-DD ligand protein
	comp	rising a	fragment of the amino acid sequence of SEQ ID NO:16; and
		(e)	a polynucleotide capable of hybridizing under stringent
	condi	tions to	any one of the polynucleotides specified in (a)-(d).
15			
	40.	The c	composition of claim 8 wherein said protein comprises an amino
	acid sequence	e select	ed from the group consisting of:
		(a)	the amino acid sequence of SEQ ID NO:16; and
		(b)	fragments of the amino acid sequence of SEQ ID NO:16;
20	said protein b	eing su	bstantially free from other mammalian proteins.
	41.		method of claim 14 wherein said TNF-R1-DD ligand protein
	comprises an	amino	acid sequence selected from the group consisting of:
		(a)	the amino acid sequence of SEQ ID NO:16; and
25		(b)	fragments of the amino acid sequence of SEQ ID NO:16.
	42.		nethod of claim 26 wherein the second polynucleotide is selected
	from the grou	-	•
		(a)	a polynucleotide comprising the nucleotide sequence of SEQ ID
30	NO:1		nucleotide 326 to nucleotide 5092;
		(b)	a polynucleotide comprising a fragment of the nucleotide
	-		SEQ ID NO:15, which encodes a protein having TNF-R1-DE
	ligand	-	n activity;
		(c)	a polynucleotide encoding an TNF-R1-DD ligand protein
35	comp	ricina t	he aming acid sequence of SEO ID NO:16:

5		(d) a	a polynucleotide encoding an TNF-R1-DD ligand protein
	compr	ising a fi	ragment of the amino acid sequence of SEQ ID NO:16 and
	having	TNF-R1	-DD ligand protein activity; and
		(e) a	a polynucleotide capable of hybridizing under stringen
	conditi	ions to an	y one of the polynucleotides specified in (a)-(d), which encodes
10	a prote	in having	g TNF-R1-DD ligand protein activity.
	43.	The cor	nposition of claim 1 wherein said polynucleotide sequence is
	selected from	the group	consisting of:
		(a) a	a polynucleotide comprising the nucleotide sequence of SEQ ID
15	NO:17	from nu	cleotide 14 to nucleotide 2404;
		(b) a	a polynucleotide comprising a fragment of the nucleotide
	sequer	ice of SE	Q ID NO:17;
		(c) a	a polynucleotide encoding an TNF-R1-DD ligand protein
	compr	ising the	amino acid sequence of SEQ ID NO:18;
20		(d) a	a polynucleotide encoding an TNF-R1-DD ligand protein
	compr	ising a fr	agment of the amino acid sequence of SEQ ID NO:18; and
		(e) a	a polynucleotide capable of hybridizing under stringen
	condit	ions to ar	y one of the polynucleotides specified in (a)-(d).
25	44.	The con	nposition of claim 8 wherein said protein comprises an amino
	acid sequence	selected	from the group consisting of:
		(a) t	he amino acid sequence of SEQ ID NO:18; and
		(b) 1	Fragments of the amino acid sequence of SEQ ID NO:18;
	said protein be	eing subs	tantially free from other mammalian proteins.
30			
	45.	The me	thod of claim 14 wherein said TNF-R1-DD ligand protein
	comprises an	amino ac	id sequence selected from the group consisting of:
		(a) t	he amino acid sequence of SEQ ID NO:18; and

(b)

fragments of the amino acid sequence of SEQ ID NO:18.

- 5 46. The method of claim 26 wherein the second polynucleotide is selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 14 to nucleotide 2404;
 - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:17, which encodes a protein having TNF-R1-DD ligand protein activity;
 - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:18;
 - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 and having TNF-R1-DD ligand protein activity; and
 - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having TNF-R1-DD ligand protein activity.